Emma M. Groarke
@emmamgroarke
🇮🇪Haematologist @nih_nhlbi l via @ucdmedicine @trinitymed1 l Lover of 🚀🐷🖖🍷l #SAA #IBMFS #telomeres #CHIP #MDS #AML #HSCT #VEXAS l Comments mine.
Really excited I got to promote our trial-in-progress for #BMFsm at #ASH24. Now recruiting! ✅👇 clinicaltrials.gov/study/NCT05998… @NealSYoung1 @bhavishap29 @aamdsif @ASH_hematology
Exciting new study underway for immune BMF including AA, LGL and hypoMDS using ruxolitinib @nih_nhlbi led by my colleague @emmamgroarke
Adoptive natural killer (NK) cell therapy may have a role to play in clonal cytopenia of unknown significance (CCUS) and could help prevent CCUS patients from developing myelodysplastic syndrome (#MDS) & #AML #leukemia NK immune cells derived from pre-leukemic bone marrow stem…
Recent article from @TheEBMT led by Pedro Prata @Haematologica looks at #HCT after clonal evolution in #SAA. Overall 5 year survival 64% in a young population. Ongoing need to develop optimal surveillance/intervention to decrease this complication haematologica.org/article/view/1…
Excited to validate our single-center @theNCI findings in this multi-center phase II study in additional patients with #lymphoma. Please consider referring patients or opening at your site if interested.
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
Pleased to see our work looking at the impact of cytokine derived therapies / steroids on hematologic progression in #VEXAS led by Benjamin Turturice @petercgrayson now published in @eular_ARD. sciencedirect.com/science/articl… @bhavishap29 @fergutierrezro1 @NealSYoung1
I've long been fascinated by the role of iron chelation- and its disordered metabolism- in MDS, particularly in the context of transplantation. This effort led by @FiekeHoff @StevenPavletic and @DrEdSchulz emerged from that curiosity. doi.org/10.1016/j.blre…
Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now published in @BloodPortfolio. >1/3 had significant infection history and nearly 1/2 t-lymphopenia. @FernandoCatto & @fergutierrezro1. ashpublications.org/blood/article-…
Safe the Date and see you in beautifull #Wien for #ESHBMFS2026 …
🗓️#ESHBMFS2026 SAVE THE DATE: Nov. 6-8, 2026 in Vienna ESH--EHA-IPIG 4th Translational Research Conference: Bone Marrow Failure & Leukaemia Predisposition Syndromes Chairs: @CarmemBonfim1 @brummendorf A. Risitano, @SharonSavageMD ➡ bit.ly/4lcJlpV #ESHCONFERENCES #bmfsm
If you’re at #ICML2025 come by my poster 1230-1300. We examine survival by anthracycline use in older cHL patients. TLDR: use anthracycline if at all possible! @DavidJCutter @graham74GC
Congratulations to the 94 clinical fellows who recently graduated from 34 fellowship and residency programs part of the Graduate Medical Education at the NIH Clinical Center! #FutureResearchers #FutureScientists #graduates #NIH #NIHExcellence #GME cc.nih.gov/training/gme
With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…
It was an honor to present on behalf the Frenvex our results on Aza in #VEXAS syndrome at #EHA2025
Remarkable work by @yash_pershad and team on CHIP dynamics over 16 years in ~7,000 women out now in @BloodPortfolio! Longitudinal CHIP studies remain rare - this depth of follow-up is invaluable. Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 16-Year…
Proud of @fiumara_martina presenting our work on #VEXAS syndrome at the @EHA_Hematology Congress today! Link to the paper: doi.org/10.1038/s41591… @SanRaffaeleMI @Fondaz_Telethon
New content online: Clonal dominance: mutations in VEXAS syndrome take advantage of inflammation bit.ly/4mQQi1q
Efficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group onlinelibrary.wiley.com/doi/10.1002/he…
Delighted to have our work on Polygenic Modifiers of #TelomereBiologyDisorders, led by @michaelpoeschla, along with @SashaGusevPosts, @mitchiela, @SharonSavageMD, @hemanth_tummala, and others, published as an advanced online paper in @jclinicalinvest today:…
Excited to share our @nih_nhlbi work led by Alice Wu in collaboration with @KingsCollegeLon published in @NatureComms using scRNAseq and CyTOF to explore pathophysiology of immune #aplasticanemia pre and post IST. nature.com/articles/s4146… @NealSYoung1 @bhavishap29 @KordastiL
Join us for Cocktails & Chromosomes - New York City on August 5th at Hogan Lovells! Celebrate our community with an elegant evening of meaningful moments. Tickets are open! Secure your spot + view sponsorships:teamtelomere.org/cocktails-chro…
🎥 In a fantastic interview from #IPIG2025, Catherine Flynn (@Catheri20663328; @stjamesdublin) discusses the characterization of breakthrough hemolysis events in pts with PNH treated with crovalimab or eculizumab on COMMODORE 1 & 2: 👉 ow.ly/w8BY50VWk5B #CTSM #RareDisease